Boston Scientific shares are trading higher after the company announced it initiated the AVANT GUARD clinical trial to evaluate the FARAPULSE Pulsed Field Ablation System as a first-line treatment for persistent atrial fibrillation.

-0.45% Pre

Boston Scientific Corporation

BSX

0.00

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.

Recommend

Citizens Reiterates Market Outperform on Salesforce, Maintains $430 Price Target

Speaking At UBS Global Technology And AI Conference, Nvidia CFO Says Most New Nvidia AI Chips Being Shipped Are Adding New Data Center Infrastructure And Not Replacing Installed Base

Euro Sun Mining: Binary Play For 2026 With 10x Permit-Rerating Potential

UPDATE 3-Canada's Scotiabank beats profit on capital markets boost and reports cautious optimism for 2026

Amazon and Adobe Deepen AI Collaboration to Advance Creativity and Marketing

If You Invested $1000 In Boston Scientific Stock 5 Years Ago, You Would Have This Much Today

Trading Wisdom | From Taxi Driver to Trading Legend: How He Turned US$3,000 into US$1.2 Billion

Acotec Scientific Gains PRC Approval for Microcatheter V-Otter